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ABSTRACT
Introduction. Migraine and vertigo are two common conditions. The main disorder connecting both these entities is vestibular 
migraine (VM). 
State of the art. VM may affect 1–3% of the general population. It is a disabling disease of recurrent attacks of vestibular symp-
toms accompanied by migraine features which occur in patients with a current or previous history of migraine. The episodes 
can last minutes, hours or even days, and may occur without any concurrent headache, which can prompt misdiagnosis. VM 
often begins several years after a typical migraine, and the delay between onset of headache and vertigo may be long. The 
diagnosis is based on the patient’s clinical history and can be challenging due to the lack of an established confirmatory diag-
nostic test or biomarkers. The mechanism of vestibular migraine remains unclear and is still under investigation, but it seems 
to be an interaction between trigeminal and vestibular systems. Due to the lack of specific trials, treatment recommendations 
are based on migraine guidelines. Several drugs seem to be effective, although there have been few randomised controlled 
trials in this area. Regardless of the published strict and detailed diagnostic criteria, this condition remains little known, and as 
a consequence is underdiagnosed and undertreated. 
Clinical implications. Efforts should be made to educate medical communities and patients about this disease and to encoura-
ge neurologists and ENT specialists to cooperate. Every patient with vertigo of unknown origin should be directly asked about 
a past or present history of migraine, or migraine symptoms experienced during their vertigo episodes. 
Future directions. There is a growing need for studies regarding the pathophysiology of VM as well as randomised trials to 
establish clear treatment recommendations and to improve management of this surprisingly common disorder.
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Introduction
Migraine and vertigo are two very prevalent conditions in the 
general population [1]. Nevertheless, a link between those 
two disorders exists: vertigo is 2-3 times more common in 
migraine patients, especially migraine with aura patients, than 
in the general population (ranging from 30 to 50%) [2, 3]. In 
addition, vertigo is reported to coexist with other migraine 
symptoms during almost half of severe migraine attacks [3]. 
It is also worth noting that vertigo can be one of the aura 
symptoms in migraine with brainstem aura, as well as a part 
of benign paroxysmal vertigo in children [4]. 
However, the main disorder which connects vertigo with 
headache is vestibular migraine (VM) (previously known as 
migrainous vertigo or migraine-associated vertigo). VM is one 
of the most common neurological disorders causing vertigo 
and dizziness [5], but despite its high prevalence and published 
diagnostic criteria, it remains surprisingly little known, and 
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thus underdiagnosed and undertreated [6]. The cause of this 
diagnostic challenge may be the wide spectrum of symptoms, 
the absence of headache in almost half of the attacks, as well as 
poor knowledge of diagnostic criteria and a lack of cooperation 
between the neurological and otolaryngological communities.
Epidemiology and demographic factors
Vestibular migraine affects approximately 1–3% of the general 
population and up to 30% of patients in specialised vertigo or 
headache centres [1, 7]. Moreover, benign paroxysmal vertigo 
of childhood is known to be an early manifestation of migraine. 
This has a 3% prevalence in children between the ages of 6 and 
12 [8]. In one study, VM was diagnosed in 10.3% of migrai-
neurs, while another determined its prevalence to be 21% in 
the migraine population [9, 10]. Chia et al. [11] reviewed 208 
patients with benign recurrent vertigo diagnosed in a neuro-
-otology clinic, and found that 87% of them met ICHD criteria 
for migraine (62% with aura), and that among migraine patients 
with vertigo and migraine 70% met the VM criteria, which is 
a surprisingly high amount. Indeed, VM patients significantly 
more often experience migraine with aura, and vestibular 
symptoms are twice as likely to be reported in patients with 
migraine with aura compared to individuals without aura [2, 3]. 
Plus, according to Martinez et al. [12], almost 40% of patients 
with VM meet criteria for chronic migraine. 
Importantly, the presence of migraine is extremely high 
in patients with recurrent unclassified vertigo (ranges from 
60–80%) [11]. VM is more prevalent in females, with a gender 
ratio of from 1.5 up to 5.1 [13–15]. The average age at onset 
of VM is 38–50 [15–17]. It is worth noting that migraine he-
adache precedes the onset of vestibular attacks, where the age 
at onset of migraine is 23–32 years, while the average age at 
onset of vertigo is 34–38 years [15, 18, 19]. Moreover, mostly 
in postmenopausal women, typical migraine attacks may be 
replaced by vestibular episodes [20]. Interestingly, the time 
gap between migraine and vestibular symptoms onset may 
be long, as patients can be headache-free for years before the 
vestibular symptoms starts [21]. The mean delay between 
the onset of headache and vertigo is 8–14 years [21, 22]. The 
majority of VM patients suffer from episodic migraine, and 
one in four of them have chronic migraine with medication 
overuse headache [15]. Most VM patients report a family hi-
story of the disorder. A history of migraine has been found in 
50.8–70.2% of cases [16]. Notably, some patients also mention 
a family history of vertigo of no clear origin, and many of 
them refer to migraine precursors, especially motion sickness 
during childhood as well as cyclic vomiting, torticollis and/or 
episodic abdominal pain [8, 16, 23]. 
Some authors have suggested that vestibular symptoms in 
paediatric patients may predispose to the development of VM 
as adults [18]. One study revealed that up to 78% of VM pa-
tients had experienced carsickness in their lifetime [24]. Other 
prevalent comorbidities in VM patients are mood disorders 
including anxiety, depression and sleep disturbance [7, 15, 25]. 
One study demonstrated that age under 40, female sex, mood 
disorders, and prior head trauma were all connected with 
significantly increased odds of developing VM [7]. VM is 
one of the most common precipitants of persistent postural 
perceptual dizziness, a newly defined disorder characterised 
by persistent dizziness and perceived instability, which is 
exacerbated in busy visual environments and in an upright 
position [26]. Approximately 40% of patients with VM have 
reported missing work because of their symptoms, which 
demonstrates the impact of this disease on daily activities 
and quality of life [1]. 
VM is an underdiagnosed disorder: a study in a tertiary 
vertigo centre demonstrated that although VM was finally 
diagnosed in 20.2% of patients, it was suspected by the refer-
ring doctor in fewer than 2% of patients [6]. Another study 
showed that only 20% of VM patients were correctly diagno-
sed after visiting a doctor [1]. Similarly, Formaister et al. [7] 
reported that only 10% of subjects meeting the criteria for 
VM were told that migraine was the cause of their dizziness. 
Misdiagnosis increases when vestibular symptoms are not 
associated with headaches and half of the patients are supposed 
to have Meniere’s Disease [15]. A survey among American 
neurologists and otorhinolaryngologists (ENT) revealed that 
a neurologist would diagnose VM in vertigo and headache 
patients more often than an ENT specialist. This finding is 
alarming because 19% of ENT specialists and 14.5% of neu-
rologists have declared that they had never treated a patient 
with VM before [27].
Our experience is that more patients with VM are found 
in otolaryngological than in neurological departments, and 
that to set up a VM diagnosis a neurological consultation 
must be performed, as most ENT specialists are unfamiliar 
with migraine diagnostic criteria.
Pathophysiology of VM
Although the pathogenesis of VM is still unclear, genetic, 
inflammatory and neurochemical mechanisms have been 
proposed, mostly based on migraine pathophysiology, as mi-
graine interacts with the vestibular system at many different 
levels [28–30]. It seems that both the central and peripheral 
vestibular systems are associated with its pathogenesis. 
First of all, many studies have highlighted the overlap 
between vestibular and migraine pathways, as the caudal pa-
rabrachial nucleus receives both afferent peripheral trigeminal 
nociceptive and vestibular input, and also the trigeminal nerve 
affects the inner ear by cochlear vasculature innervations 
[31]. So, the cause of VM may be direct central activation of 
vestibular centres by the trigeminovascular system together 
with its effects on the inner ear [32]. It seems that vestibular 
symptoms come from the vestibular nuclei, which are simulta-
neously suppressed by inhibitory feedback from the cerebellar 
nodulus and uvula [33]. There is also evidence of otolithic 
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pathway abnormalities in individuals with VM [34]. It is also 
suggested that Purkinje cells in the paraflocculus could be 
inhibited after the occurrence of a migraine episode, which 
may be an important factor leading to vestibular migraine [35]. 
Magnetic resonance studies have shown an increased thala-
mic activation in VM patients during vestibular stimulation 
compared to healthy controls, as well as grey matter volume 
abnormalities of nociceptive and multisensory vestibular 
brain areas [36, 37]. In addition, a PET study during an attack 
revealed increased metabolism in the temporo-parieto-insular 
areas and bilateral thalami as well as decreased metabolism in 
the occipital cortex [38]. Another pathophysiological mecha-
nism in VM may be a visuo-vestibular problem, as patients 
with VM have a longer duration of post-rotatory nystagmus 
compared to healthy controls or ordinary migraine patients 
[39]. Plus, a genetic component in the pathogenesis of VM 
has been identified [28, 40].
Diagnostic criteria
A VM diagnosis is based on clinical history. The International 
Headache Society (IHS) and the Barany Society have published 
a consensus document with diagnostic criteria for vestibular 
migraine added to the ICHD-3 beta (Appendix, subchapter 
‘Episodic syndromes that may be associated with migraine’) 
[4, 41] (Tab. 1). According to academic panels, VM was de-
fined as an emerging condition needing further research for 
full validation [4]. 
The basic diagnostic criteria are presented in Table 1, but 
some terms need to be broadly described. First of all, vestibular 
symptoms (as defined by the Bárány Society’s Classification 
of Vestibular Symptoms) include: spontaneous vertigo (inter-
nal — a false sensation of self-motion, or external — a false 
sensation that the visual surrounding is spinning or flowing); 
positional vertigo; visually-induced vertigo; head motion-
-induced vertigo; and head motion-induced dizziness with 
nausea. It is worth noting that to fulfill diagnostic criteria 
dizziness must be characterised by a sensation of disturbed 
spatial orientation, thus other forms of dizziness are currently 
not included in the classification of vestibular migraine [4]. 
Besides, vestibular symptoms do not include presyncope 
symptoms, mental confusion, depersonalisation, generalised 
weakness or fatigue. Moderate vestibular symptoms are defined 
as those interfering with, but not preventing, daily activities, 
while severe symptoms are those that stop daily activities. 
Although vestibular symptoms must last between five minutes 
and 72 hours, individuals with attacks lasting only for a few 
seconds may be included if the total period during which short 
attacks recur is one of at least five minutes [4].      Interestingly, 
Abouzari et al. compared patients with a diagnosis of VM by 
ICHD-3 to those who did not fulfill ICHD-3 criteria although 
they had concurrent vertigo and migraine. They found that 
both groups were very similar in their characteristics. Thus, 
adhering strictly to the ICHD-3 criteria, a nearly equivalent 
population that might benefit from migraine treatment would 
be missed. The authors concluded that the differences between 
cohorts represented selection bias, not meaningful features, so 
both groups may represent a spectrum of the same disease [42].
Clinical features
Vestibular symptoms
Most patients report internal vertigo (73%) and triggered verti-
go, while external vertigo and positional vertigo are less frequ-
ent [16, 18]. Vertigo is often described as a spinning, rocking, 
tilting, swaying and falling sensation. According to other study, 
vestibular symptoms were mainly described as like feeling 
the ground slipping (40.6%), swaying (27.7%), rocking as on 
a boat (26.7%), or stepping into an empty space (24.8%) [15]. 
Less common vertigo sensations include floating, shimmering, 
tumbling, bobbing, swimming, sliding, and multi-directional 
motion [18]. One third of patients experienced unsteadiness 
[16]. It is worth noting that most patients report more than 
one vestibular symptom during VM episodes [16]. Almost 
half of individuals complain of persistent dizziness during 
the interictal period [16]. The majority of patients continue to 
have recurrent vertigo in the long-term evolution of VM, with 
possible slow progression of vestibulo-cochlear dysfunction 
and the development of mild persistent unsteadiness [43].
Headache and other migraine features
Although the core of the disease is migraine, and according 
to diagnostic criteria migraine features must be present for 
at least half of the time along with vestibular symptoms, in 
some VM patients, headache and vestibular symptoms never 
occur together. 
In cases without headache, other associated features like 
age at onset and duration of episodes indicate that vertigo is 
a migraine equivalent. Headaches accompany VM episodes 
in almost 50% of patients; some report head fullness or head 
Table 1. Diagnostic criteria for definite vestibular migraine [4, 41]
Diagnostic criteria for definite vestibular migraine
A. At least five episodes fulfilling criteria C and D
B. Current or previous history of migraine with or without aura accor-
ding to International Classification of Headache Disorders (ICHD-3)
C. Vestibular symptoms of moderate or severe intensity, lasting 
between 5 minutes and 72 hours
D. One or more migraine features with at least 50% of the vestibular 
episodes: 
 y Headache with at least two of the following characteristics: 
unilateral location, pulsating quality, moderate or severe pain 
intensity, aggravation by routine physical activity
 y Photophobia and phonophobia
 y Visual aura
E. Not better accounted for by another ICHD-3 diagnosis or by 
another vestibular disorder.
In order to diagnose probable VM, only one of criteria B and D is 
required to be fulfilled
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pressure without headache [16]. Interestingly, headaches du-
ring VM episodes are usually less severe compared to a typical 
migraine-related headache, thus patients are more bothered 
by the vertigo than by the headache [23]. Balci et al. [44] 
confirmed that headache severity was higher in migraineurs 
than in vestibular migraineurs. During VM episodes, other 
migraine features are also observed, often without a headache, 
including nausea, photophobia, phonophobia, osmophobia, 
allodynia and vomiting [5, 18, 42]. If a patient complains of 
nausea and vomiting during their typical migraine headaches, 
they tend to experience similar symptoms during VM attacks 
more frequently [8]. The higher prevalence of migraine with 
aura (MA) seen in VM patients may reflect an association of 
MA with vascular disease and posterior circulation [22]. We 
would like to underline that patients with vertigo should be 
directly asked about migraine symptoms during their episodes, 
as they often do not volunteer them [5].
Other symptoms
Some patients report tinnitus, fullness of the ear, palpitations, 
and even mild and transient hearing loss, during their episodes 
[18]. Several authors have described an accompanying Alice in 
Wonderland Syndrome — a rare and fascinating sensory per-
ception disorder, with the symptoms of visual distortions, ex-
trapersonal misperceptions, or somesthetic distortions [16, 45]. 
Some studies show that VM patients are significantly more 
anxious and agoraphobic, have depression symptoms and 
insomnia, have higher sensitivity to separation, and are prone 
to seek medical reassurance [16, 46].
Duration of vestibular attacks 
The duration of episodes varies from a few seconds up to se-
veral days [8, 18]. According to Vuralli et al. [15], vestibular 
symptoms were described as short attacks lasting for seconds 
by 60.4% of VM patients, but the total time with repeated short 
episodes lasted between hours and days. Notably, patients 
with short-lasting attacks tend to have several such attacks 
every day [15, 19].
Triggers and aggravating factors
The top VM triggers are stress, sleep deprivation, bright lights, 
missing meals and weather changes; these do not differ from 
typical migraine triggers [16, 47]. Some attacks may be started 
by daily head and body movements, menstruation and sensory 
stimuli [5, 15]. Visually induced vestibular symptoms have 
been described by 71.3% of patients, and positional motion-
-induced vestibular symptoms by 82.2% of patients [15].
Neuro-otological examination
A neurological as well as an otological examination is usually 
normal between episodes, although mild central deficits can 
exist, mostly in patients with a long history of VM [14, 43, 48]. 
During VM episodes, most patients have a central spontaneous 
or positional nystagmus [48, 49]. The nystagmus has no latency 
period, is usually persistent and non-fatigable, and is markedly 
reduced by visual fixation [50, 51]. In addition, imbalance is 
a regular finding during acute attacks, including a positive 
Romberg test and gait ataxia [17, 49].
Differential diagnosis
VM must be differentiated particularly from Meniere’s Disease 
(MD) and benign paroxysmal peripheral vertigo (BPPV). Re-
gardless of the many differences between these disorders, one 
should remember that, at very early stages, most symptoms can 
be quite similar. Meniere’s Disease is a disorder with attacks 
of coexisting vertigo, tinnitus, aural fullness, and hearing 
loss [32]. MD is known to be associated with migraine, as the 
lifetime prevalence of migraine is higher in the MD group 
compared to controls, and almost half of MD patients may 
experience headache, photophobia or aura during Meniere’s 
attacks [32, 52]. Radtke et al. [52] reported that the lifetime 
prevalence of migraine was higher in the MD group (56%) 
than controls (25%, p < 0.001); they concluded that migraine 
and MD might share a similar pathophysiology. 
In a very large group of 911 MD patients, Pyykkö et al. 
[53] found migraine in 20.9% of subjects while headache was 
reported by 42.9%. Notably, migraine patients complained of 
more severe MD symptoms than non-migraineur patients with 
MD. Shin et al. [54] discovered an incidence of VM in 35% 
of MD patients, mostly with a probable MD diagnosis. One 
study revealed that MD patients with VM have better hearing 
and more frequent vertigo episodes than individuals without 
VM [55]. Interestingly, some patients may experience the 
clinical features of both VM and MD during their attack. This 
has been described in the literature as ‘VM/MD overlapping 
syndrome’ [56]. 
Nevertheless, many differences between these two di-
sorders exist, as individuals with MD suffer mostly from 
accompanying auditory symptoms, anxiety, and palpitations, 
while migraine sufferers experience typical headache, photo-/
phonophobia or aura [57, 58]. Endolymphatic hydrops is the 
primary pathological finding in MD patients, although Gurkov 
et al. [59] using MRI found endolymphatic hydrops in 20% of 
patients with VM and auditory symptoms. Also, other vesti-
bular tests do not completely segregate individuals with MD 
from those with VM [60, 61]. 
BPPV is another common cause of vertigo and should be 
considered in the differential diagnosis of VM patients. Notably, 
migraine is more common in patients with BPPV compared to 
controls, and having migraine is linked with an increased risk of 
developing BPPV [11, 14]. For differentiation, positional testing 
which stimulates vertiginous attacks and elicits nystagmus may 
be helpful, including the Dix-Hallpike manoeuvre or the supine 
roll test for the horizontal canal variant [62]. 
Other disorders that rarely may mimic VM, and should 
be taken into consideration during the differentiation pro-
cess, include: vertebrobasilar TIA, vascular compression of 
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the eighth nerve, autoimmune inner ear disease, insufficient 
compensation of unilateral vestibular loss, schwannoma of 
the eighth nerve, persistent postural-perceptual dizziness, and 
anxiety disorder [16, 26, 62].
Laboratory findings 
Although no pathognomonic laboratory test that can verify 
a VM diagnosis exists, investigations should be done to rule 
out any other diagnosis. Many authors report minor signs 
of peripheral and central vestibular dysfunction, including 
pathological results in caloric and video head impulse testing 
(vHIT) as well as in tonal audiometry, cervical and ocular ve-
stibular evoked myogenic potentials (VEMP), posturography 
or magnetic resonance imaging (MRI), but the findings are 
ambiguous [61, 63–71]. 
It is worth emphasising that abnormal vestibular testing 
results are also found in patients with migraine without 
a history of vestibular symptoms [72]. In most patients, tonal 
audiometry is normal [73]. The most consistent laboratory 
finding in VM is a unilaterally reduced caloric response as 
well as bilateral caloric hyporesponsiveness, but only in a small 
percentage of patients. 
Notably, individuals with VM are significantly more likely 
to have an emetic response to caloric stimulation than other 
patients [74]. Almost half of VM patients have saccadic move-
ments in vHIT [10]. Some studies have revealed that cervical 
VEMP can be used as a diagnostic test to differentiate MD from 
VM, because VEMP responses are symmetrically reduced on 
both sides in VM patients [75]. One study has demonstrated 
an absence of unilateral or bilateral VEMP response at 90 dB 
normal hearing level in almost half of VM patients, which was 
significantly higher than in healthy controls [65], while another 
showed reduced VEMP amplitudes compared to controls, 
suggesting that not only peripheral but also central vestibular 
structures are affected in VM patients [63]. 
Moreover, patients with VM have shown compromised 
body balance in static posturography tests, and higher visual 
dependency and low stability of the postural control system 
when maintaining quiet standing [67, 76]. Brain MRI is unre-
markable in VM sufferers, although some studies found that 
grey matter volume of some brain regions of patients with 
VM is significantly larger than in patients with migraine or 
healthy controls, mostly areas linked with assessment, inte-
gration and pain expectations as well as those associated with 
mood and anxiety [16, 77]. Interestingly, other authors have 
found grey matter volume reduction in the temporal gyrus, 
mid-cingulate, dorsolateral prefrontal area, insula, parietal 
and occipital cortex [78].
Vestibular migraine treatment
Due to the lack of well-conducted randomised clinical trials, 
VM treatment recommendations are mostly based on the 
guidelines for migraine therapy or observational studies, retro-
spective cohorts and open-label trials, anecdotal experience, 
and expert opinion [79–81]. We should remember that incon-
sistent definitions of VM based on old diagnostic criteria were 
used in many of these studies, thus examined cohorts were 
quite heterogeneous. Also, because of the absence of control 
groups in most of the studies it is difficult to determine if the 
improvement is spontaneous or due to treatment. Generally, 
migraine prophylactic treatments were effective in 77% of VM 
patients [19]. Surprisingly, even patients with headache and 
dizziness who did not meet VM diagnostic criteria benefit 
from prophylactic treatment of VM [82]. Regardless of the 
wide range of drugs that can be prescribed for the prophyla-
ctic treatment of VM, their effectiveness seems to be similar. 
Domínguez-Durán et al. [83], in a prospective study, reported 
that after five weeks of treatment, topiramate, amitryptyline, 
propranolol, flunarisine and acetazolamid were all equally 
effective in reducing vestibular symptoms, headache and the 
number of crises. A recent systematic review and meta-analysis 
revealed that although all treatment options showed impro-
vements in outcome parameters, due to heterogeneity and 
the lack of standardised reporting on outcomes, no preferred 
treatment modality could be determined [84]. 
All studies regarding VM acute or prophylactic treatment 
(based on the modern VM definition) are summarised in 
Table 2. Several older studies regarding treatment of so called 
migraneus vertigo, with inconsistent groups, also exist [85]. 
They showed the effectiveness of acetazolamide, topiramate, 
lamotrygine, pizotifen, flunarisine or amitryptyline in redu-
cing vertigo or headache [85]. Apart from pharmacological 
treatment, other treatments include lifestyle modification, trig-
ger avoidance, and vestibular rehabilitation, although results 
are inconsistent [86, 87]. Interestingly, recent trials of specific 
migraine neuromodulation devices (trigeminal external nerve 
stimulation and noninvasive vagus nerve stimulation) have re-
ported improvements in vertigo and headache severity without 
any side effect in the majority of VM patients [88, 89]. Because 
in recent times monoclonal anti-CGRP antibodies have been 
approved for migraine prevention, the question arises as to 
whether they might be effective in VM sufferers. Theoretically, 
they could play a role in vestibular physiology, because CGRP 
is also detected in human cochlear and vestibular end organs, 
and possibly plays a role in motion sickness [90, 91]. But as 
yet there is too little data on this topic. 
Clinical implications 
Vestibular migraine is a common cause of vertigo, and may 
affect 1-3% of the general population. It is a disabling disease 
of recurrent attacks of vestibular symptoms accompanied by 
migraine features and it occurs in patients with a current or 
previous history of migraine. The episodes can last for minu-
tes, hours or even days, and may occur without a concurrent 
headache, which can increase misdiagnosis. VM often begins 
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several years after typical migraine and there may be a con-
siderable delay between onset of headache and vertigo. The 
diagnosis is based on the patient’s clinical history. 
According to the recent consensus reached by the Inter-
national Headache Society and the Barany Society, in order 
to fulfill VM diagnostic criteria, attacks of vestibular symp-
toms connected with at least one migraine feature must be 
observed. Diagnosing vestibular migraine is a challenge, as 
there is lack of established confirmatory tests or biomarkers. 
The mechanism of vestibular migraine remains unclear and 
is still under investigation, but there is apparent interaction 
between the trigeminal and vestibular systems. Due to the 
lack of specific trials, treatment recommendations are based 
on migraine guidelines and several drugs seem to be effective, 
although there have been few randomised controlled trials. 
Regardless of the published strict and detailed diagnostic 
criteria, this condition remains little known, and as a result it 
is underdiagnosed and undertreated. 
Efforts should be made to educate medical communities 
and patients about this frequent disease and to encourage 
neurologists and ENT specialists to cooperate. It is important 
that every patient with vertigo of unknown origin should be 
directly asked about a past or present history of migraine, 
and about any migraine symptoms experienced during their 
vertigo episodes. 
In cases with coexisting migraine and vertigo, a VM diag-
nosis should always be considered. 
Future directions
There is a need for future studies in order to fully validate the 
diagnostic criteria and better characterise this disorder. Mo-
reover, well conducted randomised trials must be performed 
to establish clear treatment recommendations. Finally, efforts 
should be made to elucidate and understand the pathophy-
siology of VM, from both the clinical and the scientific per-
spectives, so as to improve management of this surprisingly 
common disorder.
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